Efficacy and Safety of Human Intravenous Immunoglobulin 10% (Panzyga®) in Patients with Primary Immunodeficiency Diseases: a Two-Stage, Multicenter, Prospective, Open-Label Study-Reference-Cited by-同舟云学术

Efficacy and Safety of Human Intravenous Immunoglobulin 10% (Panzyga®) in Patients with Primary Immunodeficiency Diseases: a Two-Stage, Multicenter, Prospective, Open-Label Study

Published:2017-07-29 Issue:6 Volume:37 Page:603-612
ISSN:0271-9142
Container-title:Journal of Clinical Immunology
language:en
Short-container-title:J Clin Immunol

Author:

Borte Michael,Melamed Isaac R.,Pulka Grazyna,Pyringer Barbara,Knutsen Alan P.,Ochs Hans D.,Kobayashi Roger H.,Kobayashi Ai Lan,Gupta Sudhir,Strach Magdalena,Smits William,Pituch-Noworolska Anna,Moy James N.

Publisher

Springer Science and Business Media LLC

Subject

Immunology,Immunology and Allergy

Link

http://link.springer.com/article/10.1007/s10875-017-0424-4/fulltext.html

Reference18 articles.

1. Parvaneh N, Casanova JL, Notarangelo LD, Conley ME. Primary immunodeficiencies: a rapidly evolving story. J Allergy Clin Immunol. 2013;131(2):314–23. doi: 10.1016/j.jaci.2012.11.051 .

2. Picard C, Al-Herz W, Bousfiha A, Casanova JL, Chatila T, Conley ME, et al. Primary immunodeficiency diseases: an update on the classification from the International Union of Immunological Societies Expert Committee for Primary Immunodeficiency 2015. J Clin Immunol. 2015;35(8):696–726. doi: 10.1007/s10875-015-0201-1 .

3. Berger M, Murphy E, Riley P, Bergman GE. Improved quality of life, immunoglobulin G levels, and infection rates in patients with primary immunodeficiency diseases during self-treatment with subcutaneous immunoglobulin G. South Med J. 2010;103(9):856–63. doi: 10.1097/SMJ.0b013e3181eba6ea .

4. Kersey JH, Spector BD, Good RA. Primary immunodeficiency diseases and cancer: the immunodeficiency-cancer registry. Int J Cancer. 1973;12(2):333–47.

5. Westerberg LS, Klein C, Snapper SB. Breakdown of T cell tolerance and autoimmunity in primary immunodeficiency—lessons learned from monogenic disorders in mice and men. Curr Opin Immunol. 2008;20(6):646–54. doi: 10.1016/j.coi.2008.10.004 .

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and Tolerability of Intravenous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy: Results of the ProCID Study;Drug Safety;2023-06-28

2. Low rates of headache and migraine associated with intravenous immunoglobulin infusion using a 15-minute rate escalation protocol in 123 patients with primary immunodeficiency;Frontiers in Immunology;2023-02-02

3. Efficacy, safety and pharmacokinetics of a new 10% normal human immunoglobulin for intravenous infusion, BT595, in children and adults with primary immunodeficiency disease;Vox Sanguinis;2022-08-09

4. Randomized trial of three IVIg doses for treating chronic inflammatory demyelinating polyneuropathy;Brain;2022-01-17

5. A systematic review of population pharmacokinetic analyses of polyclonal immunoglobulin G therapy;International Immunopharmacology;2021-08